{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T13:26:37Z","timestamp":1767705997505,"version":"3.37.3"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2016,6,7]],"date-time":"2016-06-07T00:00:00Z","timestamp":1465257600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundations of China","doi-asserted-by":"crossref","award":["81302493"],"award-info":[{"award-number":["81302493"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1007\/s12072-016-9741-6","type":"journal-article","created":{"date-parts":[[2016,6,7]],"date-time":"2016-06-07T11:54:56Z","timestamp":1465300496000},"page":"924-936","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Cost-effectiveness analysis of tenofovir disoproxil fumarate for treatment of chronic hepatitis B in China"],"prefix":"10.1007","volume":"10","author":[{"given":"Weixia","family":"Ke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanhui","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenjiang","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohua","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shudong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,6,7]]},"reference":[{"unstructured":"Safioleas M, Lygidakis NJ, Manti C. Hepatitis B today. Hepatogastroenterology 2007;54:545\u2013548","key":"9741_CR1"},{"doi-asserted-by":"crossref","unstructured":"Ganem D, Prince AM. Hepatitis B virus infection\u2013natural history and clinical consequences. N Engl J Med 2004;350:1118\u20131129","key":"9741_CR2","DOI":"10.1056\/NEJMra031087"},{"doi-asserted-by":"crossref","unstructured":"Yuan Y, Iloeje U, Li H, Hay J, Yao GB. Economic implications of entecavir treatment in suppressing viral replication in chronic hepatitis B (CHB) patients in China from a perspective of the Chinese Social Security program. Value Health 2008;11:S11\u2013S22","key":"9741_CR3","DOI":"10.1111\/j.1524-4733.2008.00362.x"},{"doi-asserted-by":"crossref","unstructured":"Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004;11:97\u2013107","key":"9741_CR4","DOI":"10.1046\/j.1365-2893.2003.00487.x"},{"doi-asserted-by":"crossref","unstructured":"Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009:50:661\u2013662","key":"9741_CR5","DOI":"10.1002\/hep.23190"},{"doi-asserted-by":"crossref","unstructured":"Mommeja-Marin H, Mondou E, Blum MR, Rousseau F. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. Hepatology 2003;37:1309\u20131319","key":"9741_CR6","DOI":"10.1053\/jhep.2003.50208"},{"unstructured":"China Guideline for Pharmacoeconomic Evaluations. China J Pharm Econ 2010;5:5\u201343","key":"9741_CR7"},{"unstructured":"The guideline of prevention and treatment for chronic hepatitis B (2010 version). Chin J Epidemiol 2011;32:405\u2013415","key":"9741_CR8"},{"doi-asserted-by":"crossref","unstructured":"EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012;57:167\u2013185","key":"9741_CR9","DOI":"10.1016\/j.jhep.2012.02.010"},{"doi-asserted-by":"crossref","unstructured":"Liaw YF, Kao JH, Priatvisuth T, Chan LY, Chien RN, Liu CJ, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008;2:263\u2013283","key":"9741_CR10","DOI":"10.1007\/s12072-008-9080-3"},{"doi-asserted-by":"crossref","unstructured":"Buti M, Brosa M, Casado MA, Rueda M, Esteban R. Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B. J Hepatol 2009;51:640\u2013646","key":"9741_CR11","DOI":"10.1016\/j.jhep.2009.04.013"},{"doi-asserted-by":"crossref","unstructured":"Deniz B, Everhard F. Cost-effectiveness simulation analysis of tenofovir disoproxil fumarate (tenofovir) in HBeAg negative (\u2212) patients with chronic hepatitis-B (CHB) in Italy and France. J Hepatol 2008;48:S210","key":"9741_CR12","DOI":"10.1016\/S0168-8278(08)60561-9"},{"doi-asserted-by":"crossref","unstructured":"He J, Bowen JM, Xie F, Goeree R. Cost-effectiveness analysis of antiviral treatments for HBeAg-positive chronic hepatitis B in Canada. Value Health 2012;15:894\u2013906","key":"9741_CR13","DOI":"10.1016\/j.jval.2012.06.005"},{"doi-asserted-by":"crossref","unstructured":"Coffin CS, Lee SS. Treatment of HBeAg-positive patients with nucleos\/tide analogues. Liver Int 2009;29:116\u2013124","key":"9741_CR14","DOI":"10.1111\/j.1478-3231.2008.01935.x"},{"doi-asserted-by":"crossref","unstructured":"Reijnders JG, Perquin MJ, Zhang N, Hansen BE, Janssen HL. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B. Gastroenterology 2010;139:491\u2013498","key":"9741_CR15","DOI":"10.1053\/j.gastro.2010.03.059"},{"doi-asserted-by":"crossref","unstructured":"McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology 2009;49:S45\u2013S55","key":"9741_CR16","DOI":"10.1002\/hep.22898"},{"doi-asserted-by":"crossref","unstructured":"McMahon BJ, Holck P, Bulkow L, Snowball M. Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus. Ann Intern Med 2001;135:759\u2013768","key":"9741_CR17","DOI":"10.7326\/0003-4819-135-9-200111060-00006"},{"unstructured":"Wu GC, Zhou WP, Zhao YR, Guo SH, Wang ZY, Zou SB, et al. Study on the natural history of chronic hepatitis B. Chin J Hepatol 2002;10:46\u201348","key":"9741_CR18"},{"unstructured":"Huang H, Zhu CW, Yu XF, Wang GS, Wang JY. The development of cirrhosis in Chinese patients with chronic hepatitis B. Hepatol Int 2007;6:437\u2013440","key":"9741_CR19"},{"doi-asserted-by":"crossref","unstructured":"Xu B, Hu DC, Rosenberg DM, Jiang QW, Lin XM, Lu JL, et al. Chronic hepatitis B: a long-term retrospective cohort study of disease progression in Shanghai, China. J Gastroenterol Hepatol 2003;18:1345\u20131352","key":"9741_CR20","DOI":"10.1046\/j.1440-1746.2003.03187.x"},{"doi-asserted-by":"crossref","unstructured":"Chen CJ, Yang HI, Iloeje UH. Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology 2009;49:S72\u2013S84","key":"9741_CR21","DOI":"10.1002\/hep.22884"},{"doi-asserted-by":"crossref","unstructured":"Chen YC, Chu CM, Yeh CT, Liaw YF. Natural course following the onset of cirrhosis in patients with chronic hepatitis B: a long-term follow-up study. Hepatol Int 2007;1:267\u2013273","key":"9741_CR22","DOI":"10.1007\/s12072-007-5001-0"},{"doi-asserted-by":"crossref","unstructured":"Hui AY, Chan HL, Leung NW, Hung LC, Chan FK, Sung JJ. Survival and prognostic indicators in patients with hepatitis B virus-related cirrhosis after onset of hepatic decompensation. J Clin Gastroenterol 2002;34:569\u2013572","key":"9741_CR23","DOI":"10.1097\/00004836-200205000-00018"},{"doi-asserted-by":"crossref","unstructured":"Wu B, Li T, Chen HF, Shen JF. Cost-effectiveness of nucleoside analog therapy for hepatitis B in China: a Markov analysis. Value Health 2010;13:592\u2013600","key":"9741_CR24","DOI":"10.1111\/j.1524-4733.2010.00733.x"},{"unstructured":"Wang SB, Wang JH, Chen J, Giri RK, Chen MH. Natural history of liver cirrhosis in south China based on a large cohort study in one center: a follow-up study for up to 5\u00a0years in 920 patients. Chin Med J (Engl) 2012;125:2157\u20132162","key":"9741_CR25"},{"doi-asserted-by":"crossref","unstructured":"Lo CM, Fan ST, Liu CL, Chan SC, Wong J. The role and limitation of living donor liver transplantation for hepatocellular carcinoma. Liver Transpl 2004;10:440\u2013447","key":"9741_CR26","DOI":"10.1002\/lt.20097"},{"doi-asserted-by":"crossref","unstructured":"Wu TJ, Chan KM, Chou HS, Lee CF, Wu TH, Chen TC, et al. Liver transplantation in patients with hepatitis B virus-related hepatocellular carcinoma: the influence of viral characteristics on clinical outcome. Ann Surg Oncol 2013;20:3582\u20133590","key":"9741_CR27","DOI":"10.1245\/s10434-013-3023-5"},{"doi-asserted-by":"crossref","unstructured":"Hou JL, Yin YK, Xu DZ, Tan DM, Niu JQ, Zhou XQ, et al. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1\u00a0year of a randomized, double-blind trial. Hepatology 2008;47:447\u2013454","key":"9741_CR28","DOI":"10.1002\/hep.22075"},{"unstructured":"Yao GB, Ren H, Xu DZ, Zhou XQ, Jia JD, Wang YM et al. Results of 3\u00a0years of continuous entecavir treatment in nucleos(t)ide-naive chronic hepatitis B patients. Chin J Hepatol 2009;17:881\u2013886","key":"9741_CR29"},{"unstructured":"Chen EQ, Zhou TY, Liu L, Liu C, Lei M, Tang H. A comparison of treatment with adefovir and entecavir for chronic hepatitis B in China: The 2-year results of a prospective study. Hepat Mon 2011;11:27\u201331","key":"9741_CR30"},{"doi-asserted-by":"crossref","unstructured":"Zeng MD, Mao YM, Yao GB, Hou JL, Wang H, Ren H, et al. Five years of treatment with adefovir dipivoxil in Chinese patients with HBeAg-positive chronic hepatitis B. Liver Int 2012;32:137\u2013146","key":"9741_CR31","DOI":"10.1111\/j.1478-3231.2011.02641.x"},{"unstructured":"Expert committee of combination treatment for chronic hepatitis B. Expert consensus of combination treatment for chronic hepatitis B. Chin J Hepatol 2012; 4:39\u201346","key":"9741_CR32"},{"doi-asserted-by":"crossref","unstructured":"Hou JL, Gao ZL, Xie Q, Zhang JM, Sheng JF, Cheng J, et al. Tenofovir disoproxil fumarate vs adefovir dipivoxil in Chinese patients with chronic hepatitis B after 48\u00a0weeks: A randomized controlled trial. J Viral Hepat 2015;22:83\u201391","key":"9741_CR33","DOI":"10.1111\/jvh.12313"},{"unstructured":"Lee S, Heathcote EJ, Sievert W, Trinh H, Kaita K, Younossi Z, et al. Tenofovir Disoproxil Fumarate (TDF) versus Adefovir Dipivoxil (ADV) in Asians with HBeAg-positive and HBeAg-negative chronic hepatitis B participating in studies 102 and 103 (poster no. 980). In 59th Annual Meeting of the American Association for the Study of Liver Diseases; 2008 Oct 31\u2013Nov 4; San Francisco (CA)","key":"9741_CR34"},{"doi-asserted-by":"crossref","unstructured":"Yao G, Chen C, Lu W, Ren H, Tan D, Wang Y, et al. Efficacy and safety of entecavir compared to lamivudine in nucleoside-naive patients with chronic hepatitis B: a randomized double-blind trial in China. Hepatol Int 2008;2:136","key":"9741_CR35","DOI":"10.1007\/s12072-007-9043-0"},{"doi-asserted-by":"crossref","unstructured":"Hou JL, Yin YK, Xu DZ, Tan DM, Niu JQ, Zhou XQ, et al. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: results at 1\u00a0year of a randomized, double-blind trial. Hepatology 2008;47:447\u2013454","key":"9741_CR36","DOI":"10.1002\/hep.22075"},{"doi-asserted-by":"crossref","unstructured":"Ha M, Zhang G, Diao S, Lin M, Wu J, Sun L, et al. Rescue therapy for lamivudine-resistant chronic hepatitis B: Adefovir monotherapy, adefovir plus lamivudine or entecavir combination therapy. Intern Med 2012;51:1509\u20131515","key":"9741_CR37","DOI":"10.2169\/internalmedicine.51.7329"},{"doi-asserted-by":"crossref","unstructured":"Yao GB, Zhu M, Cui ZY, Wang BE, Yao JL, Zeng MD. A 7-year study of lamivudine therapy for hepatitis B virus e antigen-positive chronic hepatitis B patients in China. J Dig Dis 2009;10:131\u2013137","key":"9741_CR38","DOI":"10.1111\/j.1751-2980.2009.00375.x"},{"doi-asserted-by":"crossref","unstructured":"Jia JD, Hou JL, Yin YK, Tan DM, Xu DZ, Niu JQ, et al. Two-year results of a randomized, phase III comparative trial of telbivudine vs lamivudine in Chinese patients. Hepatology 2007;46:189","key":"9741_CR39","DOI":"10.1016\/S0168-8278(07)62095-9"},{"doi-asserted-by":"crossref","unstructured":"Yuen MF, Seto WK, Fung J, Wong DK, Yuen JC, Lai CL, et al. Three years of continuous entecavir therapy in treatment-naive chronic hepatitis B patients: viral suppression, viral resistance, and clinical safety. Am J Gastroenterol 2011;106:1264\u20131271","key":"9741_CR40","DOI":"10.1038\/ajg.2011.45"},{"unstructured":"Snow-Lampart A, Chappell B, Curtis M, Zhu Y, Heathcote J, Marcellin P, et al. Week 96 resistance surveillance for HBeAg positive and negative subjects with chronic HBV infection randomized to receive tenofovir DF 300\u00a0mg QD (poster no. 977). In 59th Annual Meeting of the American Association for the Study of Liver Diseases; 2008 Oct 31\u2013Nov 4; San Francisco (CA)","key":"9741_CR41"},{"doi-asserted-by":"crossref","unstructured":"Pawlotsky JM, Dusheiko G, Hatzakis A, Lau D, Lau G, Liang TJ, et al. Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology. 2008;134:405\u2013415","key":"9741_CR42","DOI":"10.1053\/j.gastro.2007.11.036"},{"unstructured":"Beijing Municipal Commission of Development and Reform. Available from: http:\/\/service2.bjpc.gov.cn\/bjpc\/mediprice\/WesternMedicine_qry.jsp . Accessed Sep 2014","key":"9741_CR43"},{"doi-asserted-by":"crossref","unstructured":"Hu M, Chen W. Assessment of total economic burden of chronic hepatitis B (CHB)-related diseases in Beijing and Guangzhou, China. Value Health 2009;12:S89\u2013S92","key":"9741_CR44","DOI":"10.1111\/j.1524-4733.2009.00636.x"},{"unstructured":"Gao Q. Economic analysis for liver and renal transplant in a transplant center. 2007;1\u201346. China Master\u2019s Theses Full-Text Database. Available from: http:\/\/www.cnki.net . Accessed Sep 2014","key":"9741_CR45"},{"doi-asserted-by":"crossref","unstructured":"Levy AR, Kowdley KV, Iloeje U, Tafesse E, Mukherjee J, Gish R, et al. The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons. Value Health 2008;11:527\u2013538","key":"9741_CR46","DOI":"10.1111\/j.1524-4733.2007.00297.x"},{"doi-asserted-by":"crossref","unstructured":"Claxton K, Sculpher M, McCabe C, Briggs A, Akehurst R, Buxton M, et al. Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Econ 2005;14:339\u2013347","key":"9741_CR47","DOI":"10.1002\/hec.985"},{"doi-asserted-by":"crossref","unstructured":"Ke W, Liu L, Zhang C, Ye X, Gao Y, Zhou S, et al. Comparison of efficacy and safety of tenofovir and entecavir in chronic hepatitis B virus infection: a systematic review and meta-analysis. PLoS One 2014;9:e98865","key":"9741_CR48","DOI":"10.1371\/journal.pone.0098865"},{"doi-asserted-by":"crossref","unstructured":"Mendis S, Fukino K, Cameron A, et al. The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries. Bull World Health Organ 2007; 85: 279\u2013288","key":"9741_CR49","DOI":"10.2471\/BLT.06.033647"},{"doi-asserted-by":"crossref","unstructured":"Liang W, Xie J, Fu H, Wu EQ. The role of health economics and outcomes research in health care reform in China. Pharmacoeconomics 2014;32:231\u2013234","key":"9741_CR50","DOI":"10.1007\/s40273-014-0141-2"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-016-9741-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12072-016-9741-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-016-9741-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,9]],"date-time":"2019-09-09T06:17:15Z","timestamp":1568009835000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12072-016-9741-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,7]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["9741"],"URL":"https:\/\/doi.org\/10.1007\/s12072-016-9741-6","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"type":"print","value":"1936-0533"},{"type":"electronic","value":"1936-0541"}],"subject":[],"published":{"date-parts":[[2016,6,7]]}}}